Shield share price volatile over delayed Activated Factor XII (AFT) deal
This article was originally published in Clinica
Executive Summary
Shield Diagnostics' share price rose and then fell dramatically last week due to uncertainty over a potential marketing deal with another company for Shield's Activated Factor XII (AFT) heart attack prediction test.